Real-World Experience with Anti-CGRP Pathway Monoclonal Antibodies in a Large United States Healthcare Plan: Results of the Migraine Signature Study.
Saved in:
| Title: | Real-World Experience with Anti-CGRP Pathway Monoclonal Antibodies in a Large United States Healthcare Plan: Results of the Migraine Signature Study. |
|---|---|
| Authors: | Buse, Dawn C.1 (AUTHOR), Lipton, Richard B.1,2 (AUTHOR), Urman, Robert3 (AUTHOR), Vaidya, Shruti J.4 (AUTHOR), Robinson, Sarah C.4 (AUTHOR), Jacobson, Alice S.4 (AUTHOR), Scott, Alexandra B.4 (AUTHOR), Bensink, Mark E.5 (AUTHOR), Pressman, Alice R.4,6 (AUTHOR) alice.r.pressman@kp.org |
| Source: | Neurology & Therapy. Feb2026, Vol. 15 Issue 1, p401-420. 20p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 21938253 |
|---|---|
| DOI: | 10.1007/s40120-025-00872-1 |
